These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30310765)

  • 1. Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
    Nishioka N; Yamada T; Harita S; Hirai S; Katayama Y; Nakano T; Okura N; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Respir Med Case Rep; 2018; 25():261-263. PubMed ID: 30310765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report.
    Hong E; Chen XE; Mao J; Zhou JJ; Chen L; Xu JY; Tao W
    World J Clin Cases; 2022 Mar; 10(9):2836-2843. PubMed ID: 35434119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
    Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
    Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
    Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
    Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
    Liu Y
    Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
    Chougule A; Basak S
    Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.